The management of patients with rhythm problems has been revolutionized, primarily through the great advances in the engineering, manufacturing, and implantation techniques of cardiac rhythm management devices. Cardiac rhythm management (CRM) includes implantable devices, leads and accessories as well as external devices to treat and manage arrhythmia-related diseases. Specifically designed implantable devices for either too slow a heart rhythm (pacemakers) or too fast a rhythm (cardioverter defibrillators) help patients benefit as their overall health status can be improved. The CRM devices addresses heart disease and heart rhythm disorders through such systems as: pacemakers, implantable cardiac defibrillators, cardiac resynchronization therapy devices, implantable cardiac monitors and other novel implantable devices. The cardiac resynchronization therapy (CRT) device restores interventricular and intraventricular dyssynchrony in patients with heart failure (HF). The implantable cardioverter-defibrillator (ICD) manages ventricular tachycardia (VT) or fibrillation (VF) and saves lives primarily through the use of high-energy shocks, while the cardiac implantable electronic device (CIED), the electronic pacemaker, maintains cardiac contraction during bradycardia.
The global implantable cardiac rhythm management devices market segmentation is based on device type (cardiac resynchronization therapy systems – CRT defibrillators, CRT pacemakers; implantable cardioverter defibrillators systems; implantable pacemaker systems).
The global implantable cardiac rhythm management devices market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global implantable cardiac rhythm management devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global implantable cardiac rhythm management devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global implantable cardiac rhythm management devices market and profiled in this report include Abbott Laboratories Inc. (St. Jude Medical), Biotronik SE & Co. KG, Boston Scientific Corp., LivaNova PLC, and Medtronic PLC.